Debbie Rigby rounds up the latest in research news
Dutch data from the REALISE survey of adults with asthma shows 60% used short-acting beta2-agonist (SABA) three or more times in the last week. These high SABA users more frequently experienced moderate to severe exacerbations with use of antibiotics and oral steroids, more frequently visits to the emergency departments or needed an overnight hospital stay compared to low SABA users (SABA use £2 times in the last week).
Journal of Asthma and Allergy 2021:14 851–861.
A systematic review and network meta-analysis has concluded that CCBs or ARBs are preferred first-line antihypertensive treatment as they may significantly reduce the risk of dementia. CCBs were associated with lower dementia risks than ACE inhibitors, beta-blockers and diuretics; and ARBs had a lower risk than ACE inhibitors, beta-blockers and diuretics over at least 1 year follow-up. Beta-blockers were associated with an increased risk of dementia.
A systematic review and meta-analysis of 37 studies has shown pharmacist-led interventions in collaboration with primary care physicians are effective in reducing hospital readmissions, especially at 30 days follow-up. Readmission rates at 30 days were reduced by 22%. Most studies aimed to conduct medication reconciliation or review within 14 days after discharge.
Res Social Admin Pharm 2021.
Analysis of the 45 and Up Study during 2010 to 2014 reveals that only 28% of new residents with dementia saw their usual GP. Increase in number of medicines and prescribing of antipsychotics and benzodiazepines were higher for patients with a new GP than for those with their usual GP. There was no statistically significant difference in prescribing of antidepressants.